Cite
HARVARD Citation
Cohen, S. et al. (2018). Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study. Annals of the rheumatic diseases. 77 (6), pp. 914-921. [Online].